1.
|
Phase: Phase IV
Type: Diagnostic, Treatment
Status: Active
Age: 18 to 85
Sponsor: Other
Protocol IDs: COLOGEN, NCT00138060
|
|
2.
|
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: ASSO OE-1, EudraCT 2006-006647-31, NCT00525200
|
|
3.
|
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CHUL-BIO-COLON, RECF0356, INCA-RECF0356, NCT00559676
|
|
4.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: CMNa-ESO-01-2007, NCT00642239
|
|
5.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: YUNZHI-BC, NCT00647075
|
|
6.
|
Phase: Phase IV
Type: Supportive care
Status: Active
Age: 18 to 85
Sponsor: Other
Protocol IDs: GLU_07, NCT00772824
|
|
7.
|
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: Over 21
Sponsor: Other
Protocol IDs: PK01/16/08, NCT00808184
|
|
8.
|
Phase: Phase IV
Type: Prevention
Status: Approved-not yet active
Age: No age specified
Sponsor: Other
Protocol IDs: 562, NCT00847912
|
|
9.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 74
Sponsor: Other
Protocol IDs: 2009-03, NCT00868569
|
|
10.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 2009-04, NCT00874406
|
|
11.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: FRE-FNCLCC-ACCORD-11/0402, EU-20512, NCT00112658
|
|
12.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: FFCD-9902, SANOFI-FFCD-9902, LILLY-FFCD-9902, FFCD-FNCLCC-SFRO-9902, NCT00304135
|
|
13.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: FRE-FNCLCC- ACCORD-17/0707, FRE-FNCLCC- ACCORD-17/0707, EU-20848, NCT00861094
|
|
14.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: STX0206, NCT00724503
|
|
15.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CONKO 004, CCT-NAPN-16752, NCT00785421
|
|
16.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: IBCSG-22-00, EU-20119, NCT00022516, EUDRACT-2005-005666-36
|
|
17.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: NCRI-ACT-II, EU-20056, UKCCCR-ACT-II, ISRCTN26715889, NCT00025090
|
|
18.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: MRC-OE05, EU-20204, NCT00041262
|
|
19.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GRECCR-03, EU-20201, NCT00046995
|
|
20.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: LMU-ADEBAR, EU-20221, NCT00047099
|
|
21.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CALGB-80101, NCCTG-CALGB-80101, ECOG-CALGB-80101, NCT00052910
|
|
22.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NSABP-R-04, NCT00058474, CALGB-NSABP-R-04
|
|
23.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: NCRI-FOCUS2, MRC-CR09, EU-20303, NCT00070213
|
|
24.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 69
Sponsor: NCI
Protocol IDs: NCCTG-N0147, ECOG-N0147, N0147, NCT00079274
|
|
25.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: ID99-146, NCT00038402
|
